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Abstract
The use of weight loss dietary supplements is prevalent in the United States, and over the past
decade, there has been tremendous growth of the use of these products. It is well documented that
ephedra-based products are associated with various cardiovascular adverse effects. With new
restrictions placed on such products, companies are now manufacturing caffeine-based ephedra-free
herbal supplements. We present the case of 36-year old, previously healthy female who developed
malignant hypertension and aortic dissection while taking various caffeine-based dietary supplements.
Given the lack of research studies in regards to their safety and efficacy, judicious care should be
taken with the use of dietary supplements, including those designated as ephedra-free.
Introduction
The prevalence of obesity has increased markedly in the
United States. Successful weight loss strategy involves
long-term life style changes such as reducing calorie
consumption and increasing physical activity [1]. In the
United States, dietary supplements for weight loss are not
recommended for losing weight due to concerns about
efficacy and safety. Despite these rising concerns and
several United States Food and drug Administration (FDA)
warnings, supplements are an appealing alternative or
adjunct for weight management for many people. Dietary
supplements are widely available and there is little
information available on who is using these products
and how they are typically used [2]. It is well documented
that ephedra-based supplements are associated with
adverse reactions, especially cardiovascular and neurolo-
gical injuries [3–5]. With new restrictions from FDA on
ephedra, companies are now manufacturing caffeine-
based ephedra-free dietary supplements and recent reports
suggest that they may have potential, serious side effects
that are similar to that of ephedra-based products [6,7].
We report the case of a patient who developed malignant
hypertension and aortic dissection associated with the
excess use of multiple caffeine-based ephedra free weight
loss dietary supplements.
Case presentation
A 36-year-old, previously healthy Hispanic female with no
significant past medical history and no prior history of
hypertension presented to the emergency room with sharp
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165 centimeter tall and weighed 70 kilogram. She was a
housewife and mother of two living children. She smoked
one pack of cigarettes a day for more than ten years. For 3
months prior to presentation, she had been taking 18–20
tablets of caffeine-based weight loss pills daily, which was
higher than the recommended daily dose. Each tablet
contains 60–100 mg of caffeine and she was taking
1080 mg to 2000 mg of caffeine daily. She denied the
use of other medications, stimulants, herbal, alcohol and
illicit drugs. She said that she had lost approximately
20–25 kilograms in last 3 months. No family history of
hypertension, diabetes or coronary artery disease. She
denied palpitation, chest pain, insomnia, headache,
abdominal pain or increase in urination.
On presentation, her blood pressure was found to be
220/110 mm Hg in right arm and 230/118 mm Hg in left
arm. Her initial work-up included an electrocardiogram
which showed T-wave inversion in leads III, aVF and V6. A
complete blood count showed hemoglobin 12.9 g/dl
(normal: 12.0–16.0 g/dl), white blood cell count 15.1 k/ul
(normal: 4.0–11.0 k/ul) and platelet count 231 k/ul
(normal: 150–450 k/ul). Serum basic metabolic panel
showed sodium 132 mmol/L (normal:135–145 mmol/L),
potassium 3.3 mmol/L (normal:3.5–5.3 mmol/L), chlor-
ide 103mmol/L (normal:95/105 mmol/L), bicarbonate
23 mmol/L (normal:22–31 mmol/L), creatinine 1.3 mg/dl
(normal: 0.6–1.3 mg/dl), calcium 8.3 mg/dl (normal:
8.6–10.3 mg/dl), and anion gap 6 mmol/L (normal:
7–17 mmol/L). Liver function test showed normal
aspartate transaminase (15U/L; normal: 0–55 U/L),
alanine transaminase (23U/L; normal: <45 U/L), alkaline
phosphatase (55U/L; normal: 34–104 U/L) and albumin
(3.5 g/dl,normal:3.0–5.1 g/dl). Urinalysis showed only
elevated specific gravity of 1.031(normal: 1.005–1.03).
Therewerenocrystals, protein and glucose inthe urinalysis.
Troponin I level was less than 0.030 ng/ml (normal: 0.0–
0.049 ng/ml). Urine and serum toxicology screens were
negative for cocaine, amphetamine, marijuana, benzodia-
zepines, barbiturates and phencyclidine. A chest X-ray did
not show any infiltrate, consolidation, effusion or mediast-
inal widening. A computed tomography aortogram showed
aortic dissection involving the posterior aspect of the arch
extendingintothe common iliac arteriesand rightproximal
external iliac artery. The dissection extended into the left
subclavian and axillary arteries. There was narrowing of the
origin of the right renal artery due to dissection (Stanford
type B dissection) (Figure 1, Figure 2, & Figure 3).
She was started on intravenous esmolol and nitroprusside
for blood pressure control and was admitted to the
medical intensive care unit. During hospitalization, her
blood pressure remained well controlled with amlodipine.
All other investigations for a secondary cause of
hypertension were negative.Patient was discharged home
and upon follow-up 2 week later, her blood pressure
remained well controlled with low dose amlodipine.
Discussion
To our knowledge, the patient described above represents
the first reported case of aortic dissection due to malignant
Figure 1.
Aortic dissection involving the thoracic aortic arch at the mid
portion in the posterior aspect of the arch (thick arrow).
Thoracic aorta was of normal caliber (27.3 mm).
Figure 2.
Aortic dissection extending into the left subclavian and axillary
arteries and to the level of bifurcation of the common iliac
artery (thick arrows).
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dietary supplements. There has been tremendous growth
in the use of weight loss dietary supplements over the past
decade [8]. Coma, seizures, conduction abnormalities,
hypertension, hepatotoxicity, and anti-cholinergic toxicity
are previously reported medical complications attributa-
ble to inherent toxicity, adulteration, or inadvertent plant
substitutions [9,11]. Such health problems can arise from
improper use of the product; product content; product
tampering; and product defects that can alter product
quality, purity and composition [12]. A recent study
showed that caffeine-based product significantly increased
blood pressure by 9.6 mm Hg and heart rate by 16.7 beats
per minute [13].
Xenadrine EFX-a caffeine-based supplement has been
implicated in a case of exercise induced syncope associated
with QT prolongation [6]. It is important to note that the
caffeine-based product also contained a small amount of
synephrine. This raises the possibility that caffeine may be
working synergistically with synephrine to cause the
elevations in blood pressure that were seen with Xenadrine
EFX. [6]. Excessive use of caffeine-based dietary supple-
ments, presence of host of other ingredients and their
synergistic effects with caffeine, might explain the malig-
nant hypertension in our patient. She was also a chronic
smoker and it is quite possible that toxicity of high dose of
caffeine was enhanced by chronic smoking.
Conclusion
We have presented a case of potential life threatening
complication from the use of dietary supplements
marketed for weight loss. Literature review suggests that
consumers of dietary supplements tend to be less likely to
reveal their use of dietary supplements to their primary
care giver than their use of medication [14]. Providing
routine scientific based advice will be a challenge for
health care professionals because of the increasing variety
of nonprescription products on the market. It’s important
for the health care professionals to take an active role in
educating patients in routine basis to make appropriate
choices regarding the use of weight loss dietary
supplements.
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FDA, Food and Drug Administration; g/dl, Gram per
deciliter; k/ul, Thousand cells per microliter; mmol/L,
Millmole per liter; mg/dl, Milligram per deciliter; U/L,
Unit per liter; g/dl, Gram per deciliter; ng/ml, Nanogram
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Consent
Unfortunately, the patient could not be traced to obtain
written informed consent. The patient however provided
verbal consent during hospitalization for presentation and
publication of the case in medical journals. I believe that
this case report contains a worthwhile clinical lesson that
could not be made as effectively in any other way. I expect
that a reasonable person would not object to the
publication since every effort has been made so that
patient remains anonymous.
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